Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California

Drug and Alcohol Dependence

Volumn 141, Issue , 2014, Pages 99-106

  Wagner, Karla D ^a   Armenta, Richard F ^a   Roth, Alexis M ^a   Maxwell, Jane C ^b   Cuevas Mota, Jazmine ^a   Garfein, Richard S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cannabimimetics; Cathinones; Injection drug use; Synthetic drugs

Indexed keywords

CANNABINOID RECEPTOR AGONIST; CATHINONE; ALKALOID; CANNABINOID; CENTRAL STIMULANT AGENT; STREET DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CANNABIS ADDICTION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CRIMINAL JUSTICE; DRUG MISUSE; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; MULTIPLE DRUG ABUSE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; SUBSTANCE USE; UNITED STATES; DRUG USE; EPIDEMIOLOGY; MIDDLE AGED; SUBSTANCE ABUSE;

CANNABIS SATIVA;

ADULT; ALKALOIDS; CALIFORNIA; CANNABINOIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG USERS; FEMALE; HUMANS; MALE; MIDDLE AGED; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84903142856     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.05.007     Document Type: Article

References (51)

1. Aarde S.M., Angrish D., Barlow D.J., Wright M.J., Vandewater S.A., Creehan K.M., Houseknecht K.L., Dickerson T.J., Taffe M.A. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict. Biol. 2013, 18:786-799.
2. Aarde S.M., Huang P.K., Creehan K.M., Dickerson T.J., Taffe M.A. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 2013, 71:130-140.
3. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., Brandt S.D., Rothman R.B., Ruoho A.E., Cozzi N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
4. Berry-Cabán C.S., Ee J., Ingram V., Berry C.E., Kim E.H. Synthetic cannabinoid overdose in a 20-year-old male US soldier. Subst. Abuse 2012, 34:70-72.
5. Bruno R., Matthews A.J., Dunn M., Alati R., McIlwraith F., Hickey S., Burns L., Sindicich N. Emerging psychoactive substance use among regular ecstasy users in Australia. Drug Alcohol Depend. 2012, 124:19-25.
6. California Health and Safety Code § 11357.5, 2011a. Assembly Bill No. 486.
7. California Health and Safety Code § 11357.5, 2011b. Senate Bill No. 420.
8. Carbone P.N., Carbone D.L., Carstairs S.D., Luzi S.A. Sudden cardiac death associated with methylone use. Am. J. Forensic Med. Pathol. 2013, 34:26-28.
9. Centers for Disease Control and Prevention Acute kidney injury associated with synthetic cannabinoid use - multiple states, 2012. MMWR 2013, 62:93-98.
10. Coffin P.O., Galea S., Ahern J., Leon A.C., Vlahov D., Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction 2003, 98:739-747.
11. Dorairaj J.J., Healy C., McMenamin M., Eadie P.A. The untold truth about "bath salt" highs: a case series demonstrating local tissue injury. J. Plast. Reconstr. Aesthet. Surg. 2012, 65:e37-e41.
12. European Monitoring Centre for Drugs and Drug Addiction EU Drug Markets Report: A Strategic Analysis. Lisbon, Portugal 2013.
13. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 2011, 5:60.
14. Forrester M.B. 2C Series phenethylamine derivative exposures in Texas. Subst. Abuse 2013, 34:81-82.
15. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B., human immunodeficiency, and human T-lymphotrpoic viruses. Am. J. Public Health 1996, 86:655-661.
16. Gershman J.A., Fass A.D. Synthetic cathinones ('bath salts'): legal and health care challenges. P T 2012, 37:571-595.
17. Hunter L.J., Dargan P.I., Benzie A., White J.A., Wood D.M. Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM. Postgrad. Med. J. 2014, 90:133-138.
18. Jinwala F.N., Gupta M. Synthetic cannabis and respiratory depression. J. Child Adolesc. Psychopharmacol. 2012, 22:459-462.
19. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future National Survey Results on Drug Use, 1975-2012: Volume 1. Secondary School Students. 2013, The University of Michigan, Ann Arbor, MI.
20. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test. Anal. 2011, 3:552-559.
21. Kelly B.C., Wells B.E., Pawson M., Leclair A., Parsons J.T., Golub S.A. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013, 32:588-593.
22. Kirby T., Thornber-Dunwell M. High-risk drug practices tighten grip on London gay scene. Lancet 2013, 381:101-102.
23. Lankenau S.E., Clatts M.C. Patterns of polydrug use among ketamine injectors in New York City. Subst. Use Misuse 2005, 40:1381-1397.
24. Leri F., Bruneau J., Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003, 98:7-22.
25. Maxwell J.C. Psychoactive substances-some new, some old: a scan of the situation in the U.S. Drug Alcohol Depend. 2014, 134:71-77.
26. Monte A.A., Bronstein A.C., Cao D.J., Heard K.J., Hoppe J.A., Hoyte C.O., Iwanicki J.L., Lavonas E.J. An outbreak of exposure to a novel synthetic cannabinoid. N. Engl. J. Med. 2014, 370:389-390.
27. Murray B.L., Murphy C.M., Beuhler M.l. Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8:69-75.
28. NIDA Drug facts: Spice (synthetic marijuana). US Department of Health and Human Services 2012, National Institutes of Health, Rockville, MD.
29. NIDA DrugFacts: Synthetic Cathinones ("Bath Salts") 2012, http://www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-bath-salts (accessed on 8.04.13).
30. Perrone D., Helgesen R.D., Fischer R.G. United States drug prohibition and legal highs: how drug testing may lead cannabis users to Spice. Drug Educ. Prev. Polic. 2013, 20:216-224.
31. Peters A., Davies T., Richardson A. Multi-site samples of injecting drug users in Edinburgh: prevalence and correlates of risky injecting practices. Addiction 1998, 93:253-267.
32. Robertson A.M., Garfein R.S., Wagner K.D., Mehta S.R., Magis-Rodriguez C., Cuevas-Mota J., Moreno-Zuniga P.G., Strathdee S.A. Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: a binational mixed methods research agenda. Harm. Reduct. J. 2014, 11:4.
33. Russo R., Marks N., Morris K., King H., Gelvin A., Rooney R. Life-threatening necrotizing fasciitis due to 'bath salts' injection. Orthopedics 2012, 35:e124-e127.
34. Sacco L.N., Finklea K. Synthetic Drugs: Overview and Issues for Congress 2013, Congressional Research Service, Washington, DC.
35. Sanders B., Lankenau S.E., Jackson Bloom J., Hathazi D. Research chemicals": tryptamine and phenethlamine use amongst high risk youth: a pilot study. Subst. Use Misuse 2008, 43:389-402.
36. Schifano F., Corazza O., Deluca P., Davey Z., Di Furia L., Farre M., Flesland L., Mannonen M., Pagani S., Peltoniemi T., Pezzolesi C., Scherbaum N., Siemann H., Skutle A., Torrens M., Van Der Kreeft P. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int. J. Cult. Ment. Health 2009, 2:137-144.
37. Schneir A.B., Cullen J., Ly B.T. Spice" girls: synthetic cannabinoid intoxication. J. Emerg. Med. 2011, 40:296-299.
38. Shoptaw S., Montgomery B., Williams C.T., El-Bassel N., Aramrattana A., Metsch L.R., Metzger D.S., Kuo I., Bastos F.I., Strathdee S.A. Not just the needle: the state of HIV prevention science among substance users and future directions. J. AIDS 2013, 63:S174-S178.
39. Thomas S., Bliss S., Malik M. Suicidal ideation and self-harm following K2 use. J. Okla. State Med. Assoc. 2012, 105:430-433.
40. US Drug Enforcement Administration DEA Special Testing and Research Laboratory Update on Synthetics. NIDA Community Epidemiology Working Group January Meeting, Online Conference Proceedings 2014.
41. US Drug Enforcement Administration Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I 2014, http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm (accessed on 30.02.14).
42. Van Hout M.C., Bingham T. A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int. J. Drug Policy 2012, 23:188-197.
43. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012, 120:238-241.
44. Wagner K.D., Jackson Bloom J., Hathazi D., Sanders B., Lankenau S.E. Gender differences in control over drug acquisition, preparation and injection: implications for HIV and HCV risk among young injection drug users. ISRN Addict. 2013, 2013:1-9.
45. Wells D.L., Ott C.A. The "new" marijuana. Ann. Pharmacother. 2011, 45:414-417.
46. Winstock A.R., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
47. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
48. Wish E.D., Artigiani E.E., Billing A.S. Community Drug Early Warning System: The CDEWS Pilot Project 2013, Office of National Drug Control Policy. Executive Office of the President, Washington, DC.
49. Wyman J.F., Lavins E.S., Engelhart D., Armstrong E.J., Snell K.D., Boggs P.D., Taylor S.M., Norris R.N., Miller F.P. Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts". J. Anal. Toxicol. 2013, 37:182-185.
50. Zawilska J.B., Wojcieszak J. Designer cathinones - an emerging class of novel recreational drugs. Forens. Sci. Int. 2013, 231:42-53.
51. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch. Arztebl. Int. 2009, 106:464-467.